Abstract:
A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.
Abstract:
A shifter includes a powered pawl mechanism that selectively engages a shift gate. The powered pawl mechanism may include an electrically operated solenoid or the like, and may be mounted to the base of the shifter or to the shift lever. The pawl engages a shift gate that is mounted on the other of the shift lever and the base. A mechanical override may be utilized to disengage the pawl. The shifter includes an electrically operated push button or the like on the shift knob, and may utilize sensors that determine the shift lever position for controlling a transmission.
Abstract:
An injection molding apparatus comprising: a pneumatically driven actuator having a piston mounted within a fluid sealed chamber for slidable axial movement along or against an interior surface of the fluid sealed chamber via a non-elastomeric engagement or with a non-elastomeric material disposed between the piston and the interior surface of the fluid sealed chamber, the piston forming first and second drive chambers within the fluid sealed chamber, each drive chamber having respective fluid flow ports, a source of pressurized gas that generates gas flow at a selected maximum pressure or flow rate, a gas metering mechanism, a controller interconnected to the gas metering mechanism, the controller controllabiy moving the gas metering mechanism to selectable positions that correspond to reduced pressures or reduced flow rates during the course of pin travel from the fully downstream gate closed position to the fully upstream gate open position.
Abstract:
An injection molding machine (1000) having first and second nozzles (1093, 1095) for delivering melt material to first and second mold cavities (1308, 1328) of first and second molds (1010, 1020) respectively, apparatus for controlling delivery of the melt material from the nozzles to the mold cavities, each nozzle having an exit aperture communicating with a gate of a cavity of a respective mold and being associated with an actuator (1300, 1320) interconnected to a melt flow controller, the apparatus comprising a sensor (1304, 1306, 1324, 1326) for sensing a selected condition of the melt material through at least one of the nozzles; an actuator controller interconnected to each actuator, the actuator controller interconnected to the actuator associated with the at least one nozzle comprising a computer interconnected to the sensor, the computer receiving a signal representative of the selected condition sensed by the sensor, the computer including an algorithm utilizing a value corresponding to a signal received from the sensor.
Abstract:
In a method for quantitating an analyte by measuring time resolved transfer of fluorescence energy to or from a label quantitatively associated with the analyte, the present invention provides an improvement comprising measuring the energy transferred from donor compounds having the ability to absorb light energy and then transfer this energy to cross-linked allophycocyanin in a time-resolved manner, where the cross-linked allophycocyanin used according to this invention has not been exposed to strongly chaotropic agents after cross-linking.
Abstract:
An apparatus for expanding the matrix of a polymer material injected under pressure into the cavity (60c) of a mold (60), the apparatus comprising: an injection machine having a barrel (70) into which a selected polymer material is delivered, the barrel (70) comprising an elongated tubular passage terminating at a downstream end in a barrel exit port (74), the polymer material being converted within the barrel (70) to a fluid that travels as a flow under pressure; a manifold (50), one or more nozzles (64) each having a downstream exit port sealably communicating with a corresponding gate in the cavity (60c) of the mold (60); and, an injecting system (30, 30h, 30n) having an exit or outlet port (X) sealably communicating with an inlet (40) to the manifold (50) or with a channel to the manifold or with one or more of the nozzles, the injecting system injecting a selected inert fluid into the pressurized fluid polymer material.
Abstract:
A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.
Abstract:
An apparatus for expanding the matrix of a polymer material injected under pressure into the cavity (60c) of a mold (60), the apparatus comprising: an injection machine having a barrel (70) into which a selected polymer material is delivered, the barrel (70) comprising an elongated tubular passage terminating at a downstream end in a barrel exit port (74), the polymer material being converted within the barrel (70) to a fluid that travels as a flow under pressure; a manifold (50), one or more nozzles (64) each having a downstream exit port sealably communicating with a corresponding gate in the cavity (60c) of the mold (60); and, an injecting system (30, 30h, 30n) having an exit or outlet port (X) sealably communicating with an inlet (40) to the manifold (50) or with a channel to the manifold or with one or more of the nozzles, the injecting system injecting a selected inert fluid into the pressurized fluid polymer material.
Abstract:
An injection molding apparatus and system are provided in which the rate of material flow during the injection cycle is controlled. According to one preferred embodiment, an injection molding system is provided that includes an injection molding machine including a hydraulic power source, a manifold for distributing material injected from said injection molding machine to a plurality of gates leading to one or more mold cavities, and a controller to individually control respective rates at which material is injected through said gates during an injection cycle. The controller is coupled to the hydraulic power source and the hydraulic power source supplies hydraulic power to both the injection molding machine and to control said respective rates.
Abstract:
An injection molding apparatus comprising: a pneumatically driven actuator having a piston mounted within a fluid sealed chamber for slidable axial movement along or against an interior surface of the fluid sealed chamber via a non-elastomeric engagement or with a non-elastomeric material disposed between the piston and the interior surface of the fluid sealed chamber, the piston forming first and second drive chambers within the fluid sealed chamber, each drive chamber having respective fluid flow ports, a source of pressurized gas that generates gas flow at a selected maximum pressure or flow rate, a gas metering mechanism, a controller interconnected to the gas metering mechanism, the controller controllabiy moving the gas metering mechanism to selectable positions that correspond to reduced pressures or reduced flow rates during the course of pin travel from the fully downstream gate closed position to the fully upstream gate open position.